Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Int J Gynecol Pathol. 2012 Jul;31(4):337-43. doi: 10.1097/PGP.0b013e31823ff422.
Patients with low-stage, low-grade endometrial adenocarcinomas have a favorable prognosis; however, a subset has a risk of recurrence and death. We were interested in evaluating patterns of myometrial invasion and correlating them with clinical outcome to potentially identify patients at increased risk. A total of 324 cases of low-stage Grade 1 endometrial adenocarcinoma were reviewed to identify those with myoinvasion. The myoinvasive cases were classified on the basis of the pattern of invasion: infiltrating glands, microcystic elongated and fragmented (MELF; a distinctive histologic variant of the infiltrative gland pattern), broad front, adenomyosis like, and adenoma malignum. Depth of invasion and lymphovascular invasion were recorded, and a clinical follow-up of at least 2 y was obtained, as most recurrences occur in this time frame. Ninety-eight of 324 (30%) cases were invasive; 75 had >2 y of follow-up, with an average length of follow-up of >7 y (range, 24-154 mo; mean 87 mo). All patients had a hysterectomy and bilateral salpingo-oophorectomy; 39 (52%) also underwent a lymphadenectomy. Twenty-seven (36%) were superficially invasive (<10% myoinvasion), 42 (56%) invaded 10% to 49%, and 6 (8%) invaded >50%. Six (8%) cases exhibited cervical stromal invasion (Stage II); the rest were Stage I (65 IA, 4 IB). The invasive patterns consisted of infiltrative glands (48; 65%), a broad front (16; 21%), MELF (5; 7%), adenomyosis like (5; 7%), and adenoma malignum like (1, 1%). There were 65 Stage 1A cases and, of these, the myoinvasive pattern was as follows: 41 infiltrating glands, 15 broad front, 5 MELF, and 4 adenomyosis like. There were 4 Stage IB cases, of which 2 had infiltrating glands, 1 had adenoma malignum, and 1 displayed adenomyosis-like invasion. Six (8%) cases had cervical stromal invasion (Stage II), of which 5 had an infiltrative pattern of growth and 1 displayed a broad front. Lymphovascular invasion was noted in 6 cases (8%), all of which had infiltrative glands. The majority of Grade 1 endometrioid endometrial adenocarcinomas do not invade the myometrium. In cases with invasion, the infiltrative gland pattern was associated with higher stage, (3/4 Stage IB, 5/6 Stage II), lymphovascular invasion (4/6 cases), and recurrence (2/75 cases), suggesting that this growth pattern may be associated with tumors having other histologic features typically associated with more aggressive behavior.
患者患有低分期、低级别子宫内膜腺癌,预后良好;然而,有一部分患者有复发和死亡的风险。我们有兴趣评估肌层浸润模式,并将其与临床结果相关联,以潜在地识别具有更高风险的患者。总共回顾了 324 例低分期、1 级子宫内膜腺癌病例,以确定肌层浸润病例。肌层浸润病例根据浸润模式进行分类:浸润性腺体、微囊性拉长和碎片化(MELF;浸润性腺体模式的一种独特组织学变体)、广泛前沿、腺肌病样和腺瘤恶性。记录了浸润深度和脉管浸润,并获得了至少 2 年的临床随访,因为大多数复发发生在这个时间范围内。324 例中有 98 例(30%)为浸润性;75 例有 >2 年的随访,平均随访时间 >7 年(范围,24-154 个月;平均 87 个月)。所有患者均接受了子宫切除术和双侧输卵管卵巢切除术;39 例(52%)还进行了淋巴结切除术。27 例(36%)为浅层浸润(<10%肌层浸润),42 例(56%)浸润 10%-49%,6 例(8%)浸润>50%。6 例(8%)出现宫颈间质浸润(Ⅱ期);其余为Ⅰ期(65 例ⅠA,4 例ⅠB)。浸润模式包括浸润性腺体(48;65%)、广泛前沿(16;21%)、MELF(5;7%)、腺肌病样(5;7%)和腺瘤恶性样(1;1%)。有 65 例ⅠA 期病例,其中肌层浸润模式如下:41 例浸润性腺体,15 例广泛前沿,5 例 MELF,4 例腺肌病样。有 4 例ⅠB 期病例,其中 2 例为浸润性腺体,1 例为腺瘤恶性,1 例为腺肌病样浸润。6 例(8%)有宫颈间质浸润(Ⅱ期),其中 5 例有浸润性生长模式,1 例有广泛前沿。6 例(8%)有脉管浸润,均为浸润性腺体。大多数 1 级子宫内膜样腺癌不侵犯肌层。在有浸润的病例中,浸润性腺体模式与较高的分期(4/4 例ⅠB,5/6 例Ⅱ期)、脉管浸润(4/6 例)和复发(2/75 例)相关,提示这种生长模式可能与具有其他组织学特征的肿瘤相关,这些特征通常与更具侵袭性的行为相关。